Goldline Pharmaceutical share news, announcements and annual reports
BSE: 544759Pharmaceuticals & BiotechnologySmall Cap
GOLDLINE PHARMACEUTICAL LIMITED · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 2026
Last close ₹31.20up ₹0.70 (2.30%)
Share price at the BSE close on 29 Oct 2026. Previous close ₹30.50.
29 Oct: open ₹31.10, high ₹31.20, low ₹31.10
Range of traded prices from listing on 19 May 2026 to 29 Oct 2026
₹28.13Low, 21 Oct 2026₹60.00High, 19 May 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹30 Cr3,537th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 7.28
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.10
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonesince listing in May 2026
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 28.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.64
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 9,000
Goldline Pharmaceutical board and management
2 filed, newest first.
Jul 2026
Jun 2026